• Burgering, B.M., 2008. A brief introduction to foxology. Oncogene 27, 2258–2262.

  • Carbajo-Pescador, S., Mauriz, J.L., Garcia-Palomo, A., Gonzalez-Gallego, J., 2014. Foxo proteins: regulation and molecular targets in liver cancer. Curr. Med. Chem. 21, 1231–1246.

  • Chen, C., Wu, M., Zhang, W., Lu, W., Zhang, M., Zhang, Z., Zhang, X., Yuan, Z., 2016. Microrna-939 restricts hepatitis b virus by targeting jmjd3-mediated and c/ebpα-coordinated chromatin remodeling. Sci. Rep. 6, 35974.

  • Chen, J., Lu, Y., Tian, M., Huang, Q., 2019. Molecular mechanisms of foxo1 in adipocyte differentiation. J. Mol. Endocrinol. 62, R239–r253.

  • Cho, H.J., Jeong, S.G., Park, J.E., Han, J.A., Kang, H.R., Lee, D., Song, M.J., 2013. Antiviral activity of angelicin against gammaherpesviruses. Antivir. Res. 100, 75–83.

  • Choi, J.G., Lee, H., Hwang, Y.H., Lee, J.S., Cho, W.K., Ma, J.Y., 2017. Eupatorium fortunei and its components increase antiviral immune responses against rna viruses. Front. Pharmacol. 8, 511.

  • Graves, D.T., Milovanova, T.N., 2019. Mucosal immunity and the foxo1 transcription factors. Front. Immunol. 10, 2530.

  • Hanson, C.V., Riggs, J.L., Lennette, E.H., 1978. Photochemical inactivation of DNA and rna viruses by psoralen derivatives. J. Gen. Virol. 40, 345–358.

  • Hearst, J.E., Thiry, L., 1977. The photoinactivation of an rna animal virus, vesicular stomatitis virus, with the aid of newly synthesized psoralen derivatives. Nucleic Acids Res. 4, 1339–1347.

  • Hedrick, S.M., 2009. The cunning little vixen: foxo and the cycle of life and death. Nat. Immunol. 10, 1057–1063.

  • Hong, X., Luckenbaugh, L., Mendenhall, M., Walsh, R., Cabuang, L., Soppe, S., Revill, P.A., Burdette, D., Feierbach, B., Delaney, W., Hu, J., 2021. Characterization of hepatitis b precore/core-related antigens. J. Virol. 95, e01695–20.

  • Ioannilli, L., Ciccarone, F., Ciriolo, M.R., 2020. Adipose tissue and foxo1: bridging physiology and mechanisms. Cells 9, 849.

  • Kim, D.H., Kang, H.S., Kim, K.H., 2016. Roles of hepatocyte nuclear factors in hepatitis b virus infection. World J. Gastroenterol. 22, 7017–7029.

  • Maves, R.C., Castillo Ore, R.M., Porter, K.R., Kochel, T.J., 2010. Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice. Clin. Vaccine Immunol. 17, 304–306.

  • Maves, R.C., Ore, R.M., Porter, K.R., Kochel, T.J., 2011. Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in aotus nancymaae monkeys. Vaccine 29, 2691–2696.

  • Mazzaro, C., Dal Maso, L., Visentini, M., Gitto, S., Andreone, P., Toffolutti, F., Gattei, V., 2019. Hepatitis b virus-related cryogobulinemic vasculitis. The role of antiviral nucleot(s)ide analogues: a review. J. Intern. Med. 286, 290–298.

  • Musajo, L., Rodighiero, G., Colombo, G., Torlone, V., Dallacqua, F., 1965. Photosensitizing furocoumarins: interaction with DNA and photo-inactivation of DNA containing viruses. Experientia 21, 22–24.

  • Oropeza, C.E., Tarnow, G., Sridhar, A., Taha, T.Y., Shalaby, R.E., McLachlan, A., 2020. The regulation of hbv transcription and replication. Adv. Exp. Med. Biol. 1179, 39–69.

  • Parvez, M.K., Tabish Rehman, M., Alam, P., Al-Dosari, M.S., Alqasoumi, S.I., Alajmi, M.F., 2019. Plant-derived antiviral drugs as novel hepatitis b virus inhibitors: cell culture and molecular docking study. Saudi Pharmaceut. J. 27, 389–400.

  • Phillips, S., Mistry, S., Riva, A., Cooksley, H., Hadzhiolova-Lebeau, T., Plavova, S., Katzarov, K., Simonova, M., Zeuzem, S., Woffendin, C., Chen, P.J., Peng, C.Y., Chang, T.T., Lueth, S., De Knegt, R., Choi, M.S., Wedemeyer, H., Dao, M., Kim, C.W., Chu, H.C., Wind-Rotolo, M., Williams, R., Cooney, E., Chokshi, S., 2017. Peginterferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis b patients. Front. Immunol. 8, 621.

  • Pierra Rouviere, C., Dousson, C.B., Tavis, J.E., 2020. Hbv replication inhibitors. Antivir. Res. 179, 104815.

  • Quasdorff, M., Protzer, U., 2010. Control of hepatitis b virus at the level of transcription. J. Viral Hepat. 17, 527–536.

  • Ren, Y., Song, X., Tan, L., Guo, C., Wang, M., Liu, H., Cao, Z., Li, Y., Peng, C., 2020. A review of the pharmacological properties of psoralen. Front. Pharmacol. 11, 571535.

  • Schneider, K., Wronka-Edwards, L., Leggett-Embrey, M., Walker, E., Sun, P., Ondov, B., Wyman, T.H., Rosovitz, M.J., Bohn, S.S., Burans, J., Kochel, T., 2015. Psoralen inactivation of viruses: a process for the safe manipulation of viral antigen and nucleic acid. Viruses 7, 5875–5888.

  • Shen, C., Feng, X., Mao, T., Yang, D., Zou, J., Zao, X., Deng, Q., Chen, X., Lu, F., 2020. Yinyang 1 and hbx protein activate hbv transcription by mediating the spatial interaction of cccdna minichromosome with cellular chromosome 19p13.11. Emerg. Microb. Infect. 9, 2455–2464.

  • Shlomai, A., Shaul, Y., 2009. The metabolic activator foxo1 binds hepatitis b virus DNA and activates its transcription. Biochem. Biophys. Res. Commun. 381, 544–548.

  • Song, P.S., Tapley Jr., K.J., 1979. Photochemistry and photobiology of psoralens. Photochem. Photobiol. 29, 1177–1197.

  • Turton, K.L., Meier-Stephenson, V., Badmalia, M.D., Coffin, C.S., Patel, T.R., 2020. Host transcription factors in hepatitis b virus rna synthesis. Viruses 12, 160.

  • Wang, Y., Tian, H., 2017. Mir-101 suppresses hbv replication and expression by targeting foxo1 in hepatoma carcinoma cell lines. Biochem. Biophys. Res. Commun. 487, 167–172.

  • World health organization hepatitis b fact sheet. WHO. https://www.who.int/news-room/fact-sheets/detail/hepatitis-B (Accessed on 18 September 2021).

  • Wollowitz, S., 2001. Fundamentals of the psoralen-based helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin. Hematol. 38, 4–11.

  • Xing, Y.Q., Li, A., Yang, Y., Li, X.X., Zhang, L.N., Guo, H.C., 2018. The regulation of foxo1 and its role in disease progression. Life Sci. 193, 124–131.

  • Xu, Y.B., Yang, L., Wang, G.F., Tong, X.K., Wang, Y.J., Yu, Y., Jing, J.F., Feng, C.L., He, P.L., Lu, W., Tang, W., Zuo, J.P., 2014. Benzimidazole derivative, bm601, a novel inhibitor of hepatitis b virus and hbsag secretion. Antivir. Res. 107, 6–15.

  • Yamagata, K., Yoshimochi, K., Daitoku, H., Hirota, K., Fukamizu, A., 2007. Bile acid represses the peroxisome proliferator-activated receptor-gamma coactivator-1 promoter activity in a small heterodimer partner-dependent manner. Int. J. Mol. Med. 19, 751–756.

  • Yang, L., Shi, L.P., Chen, H.J., Tong, X.K., Wang, G.F., Zhang, Y.M., Wang, W.L., Feng, C.L., He, P.L., Zhu, F.H., Hao, Y.H., Wang, B.J., Yang, D.L., Tang, W., Nan, F.J., Zuo, J.P., 2014. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis b virus replication through blocking pregenomic rna encapsidation. Acta Pharmacol. Sin. 35, 410–418.

  • Yang, L., Wang, Y.J., Chen, H.J., Shi, L.P., Tong, X.K., Zhang, Y.M., Wang, G.F., Wang, W.L., Feng, C.L., He, P.L., Xu, Y.B., Lu, M.J., Tang, W., Nan, F.J., Zuo, J.P., 2016. Effect of a hepatitis b virus inhibitor, nz-4, on capsid formation. Antivir. Res. 125, 25–33.

  • Yang, L., Pei, R.J., Li, H., Ma, X.N., Zhou, Y., Zhu, F.H., He, P.L., Tang, W., Zhang, Y.C., Xiong, J., Xiao, S.Q., Tong, X.K., Zhang, B., Zuo, J.P., 2021. Identification of sars-cov-2 entry inhibitors among already approved drugs. Acta Pharmacol. Sin. 42, 1347–1353.

  • Zhang, M., Dong, W., Li, Z., Xiao, Z., Xie, Z., Ye, Z., Liu, S., Li, R., Chen, Y., Zhang, L., Wang, M., Liang, H., Baihetiyaer, R., Apaer, R., Dong, Z., Liang, X., 2021. Effect of forkhead box o1 in renal tubular epithelial cells on endotoxin-induced acute kidney injury. Am. J. Physiol. Ren. Physiol. 320, F262–f272.